LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate. April 15, 2020 04:14 AM Eastern Daylight Time.

Leo Pharma, Oneness Biotech and Microbio Shanghai have entered into a worldwide exclusive licensing agreement for FB825, a novel atopic dermatitis and allergic asthma drug candidate, according to ...

Leo Pharma A/S, of Ballerup, Denmark, has eyed a stronger company presence in Asia during the past year and took a giant step to achieving it by signing a worldwide exclusive licensing agreement with ...

Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has today announced the appointment of Paul Perreault as a strategic advisor.

According to an April 15, 2020 press release, Leo Pharma has signed the exclusive worldwide agreement with Oneness Biotech from Taiwan and Microbio Shanghai from China. Under the terms of the ...

Microbio has developed a pathogen test to help identify “a silent killer” that is notoriously difficult to predict, diagnose and treat. Morganne Kopittke Sep 22, 2023 5 min read ...

Leo Pharma is paying $40 million upfront and $530 million in biobucks to license a midstage experimental eczema and asthma drug. The therapy, FB825, has been developed by Oneness Biotech and ...

BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointed Paul Brennan as ...

Early recognition of sepsis symptoms is vital for swift intervention. However, as per Dr Flavia Huygens, the Executive Director, Co-Founder and Chief Scientific Officer at Queensland based biotech ...